Approach to the Patient with Achondroplasia—New Considerations for Diagnosis, Management, and Treatment
Top Cited Papers
Open Access
- 15 January 2025
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (7) , e2309-e2316
Abstract
Achondroplasia is the most common disproportionate short-stature skeletal dysplasia. Features associated with achondroplasia are rhizomelia, macrocephaly, midface hypoplasia, and typical cognition. Potential medical complications include foramen magnum stenosis, hydrocephalus, middle ear dysfunction, obstructive and central sleep apnea, spinal stenosis, and genu varum. Recently, vosoritide, a C-type natriuretic peptide analogue, was approved by the Food and Drug Administration with the primary indication of increasing linear growth in all children with achondroplasia and open growth plates. Due to this, pediatric endocrinologists suddenly are encountering infants and children with achondroplasia in their clinic whose families are seeking treatment with vosoritide. There is an urgent need to provide practical guidance pertaining to the diagnosis, management, and surveillance of these patients. Specific to current clinical use of vosoritide and other growth-modulating therapies in development for patients with achondroplasia, it is important to recognize that 1. some children and their families do not automatically desire such treatment, 2. not all treated children exhibit a response in linear growth, and 3. treatment does not negate the necessity of actively surveilling for the potential complications of achondroplasia that are part of its natural history. The goal of this paper is to provide probable, contemporary clinical scenarios of infants and children with achondroplasia who may present to an endocrinologist. This information is especially crucial to the endocrinologist when there is no specialized skeletal dysplasia center near the family.Keywords
This publication has 40 references indexed in Scilit:
- Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical PracticeAdvances in Therapy, 2023
- Burden and Treatment of Achondroplasia: A Systematic Literature ReviewAdvances in Therapy, 2023
- Parents’ Experience of Administering Vosoritide: A Daily Injectable for Children with AchondroplasiaAdvances in Therapy, 2023
- Birth prevalence of achondroplasia: A systematic literature review and meta‐analysisAmerican Journal of Medical Genetics Part A, 2020
- Weight gain velocity in infants with achondroplasiaAmerican Journal of Medical Genetics Part A, 2019
- Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasiaAmerican Journal of Obstetrics and Gynecology, 2018
- Optimal non‐invasive diagnosis of fetal achondroplasia combining ultrasonography with circulating cell‐free fetal DNA analysisUltrasound in Obstetrics & Gynecology, 2018
- A height‐for‐age growth reference for children with achondroplasia: Expanded applications and comparison with original reference dataAmerican Journal of Medical Genetics Part A, 2017
- Prenatal diagnosis of achondroplasia: new specific signsPrenatal Diagnosis, 2009
- Weight for age charts for children with achondroplasiaAmerican Journal of Medical Genetics Part A, 2007